ClinicalTrials.gg
Not yet recruitingNCT07776730Updated Aug 20, 2026

Keverprazan vs Pantoprazole for the Treatment of ANVUGIB

An interventional study of Pantoprazole and Keverprazan in Non-variceal Upper Gastrointestinal Bleeding, sponsored by General Hospital of Shenyang Military Region. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
908
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Acute non-variceal upper gastrointestinal bleeding (ANVUGIB) is a common medical emergency requiring hospitalization. The cornerstone of ANVUGIB management is effective gastric acid suppression. Potassium-competitive acid blockers (P-CABs) represent a novel class of gastric acid secretion inhibitors, which can rapidly and consistently increase intragastric pH. Keverprazan, a novel P-CAB, has been shown to be effective in treating duodenal ulcers and erosive esophagitis. Herein, we have designed a multicenter randomized controlled trial (RCT) to determine whether keverprazan is noninferior to pantoprazole in preventing rebleeding after successful initial hemostasis in patients with ANVUGIB.

Read the detailed description

This is a non-inferiority, randomized controlled trial. A total of 908 patients will be enrolled and stratified into high- and low-risk bleeding groups according to the GBS. Patients in the high-risk group will continue to receive high-dose intravenous PPI at a dosage of 8mg/h for 72 hours; and then those without rebleeding during this period will be randomized. Patients in the low-risk group will directly randomized. Eligible patients will be randomly assigned in a 1:1 ratio to receive keverprazan or pantoprazole. The primary endpoint will be the 14-day incidence of rebleeding. Secondary endpoints will include 1) the proportion of patients receiving blood transfusion, 2) additional endoscopic hemostasis or surgical or radiologic intervention, 3) all-cause mortality, and 4) adverse events within 14 days.

02

Conditions studied

  • Non-variceal Upper Gastrointestinal Bleeding

Keywords

  • non-variceal upper gastrointestinal bleeding
  • proton pump inhibitors
  • potassium-competitive acid blockers
  • keverprazan
  • pantoprazole
03

In context

Lead sponsor

General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants presented with hematemesis, melena, or other clinical manifestations suggestive of upper gastrointestinal bleeding within 5 days before screening.
  2. Participants have endoscopic confirmation of a non-variceal source of upper gastrointestinal bleeding.
  3. Participants are aged between 18 and 75 years.
  4. Participants who are willing to participate in this clinical trial and sign the written .

Exclusion criteria

Exclusion criteria are as follows:

  1. Participants have experienced failure of endoscopic hemostasis, rebleeding before randomization, or a requirement for immediate transcatheter arterial embolization or surgery at the time of eligibility assessment.
  2. Participants have an active or malignancy expected to interfere with survival, outcome assessment, treatment adherence, or follow-up.
  3. Participants have esophageal or gastric varices or portal hypertensive gastropathy identified during endoscopic examination.
  4. Participants who are unable to swallow the study medication.
  5. Participants have a history of partial or total gastrectomy, gastric bypass surgery, or other major surgery.
  6. Severe organ dysfunction, including any of the following: Severe hepatic or renal impairment; Unstable or severe cardiovascular, respiratory, neurological, or other systemic disease.
  7. Zollinger-Ellison syndrome.
  8. Any to keverprazan or pantoprazole, including known to either medication or any of their components.
  9. Pregnancy or lactation.
  10. Participation in another clinical study within 3 months before enrollment.
  11. Other situations considered by the investigator as unsuitable for enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
908 participants (estimated)

Study arms

  • Experimental
    Keverprazan group

    Participants will receive oral Keverprazan 20 mg once daily for 14 days.

    Drug: Keverprazan

  • Active comparator
    Pantoprazole group

    Participants will receive oral Pantoprazole 40 mg once daily for 14 days.

    Drug: Pantoprazole

Interventions

  • Participants will receive oral Pantoprazole 40 mg once daily for 14 days.

  • Participants will receive oral Keverprazan 20 mg once daily for 14 days.

06

What researchers measure

Primary outcomes

  1. Incidence of rebleeding.

    The proportion of patients who experience at least one episode of rebleeding after initial hemostasis from randomization up to Day 14. Rebleeding is defined as the recurrence of bleeding after initial hemostasis, including repeated hematemesis and/or melena, hemodynamic instability, or a decrease in hemoglobin of more than 2g/dL. The proportion will be calculated as the number of patients with rebleeding divided by the total number of patients assigned.

    Time frame: From randomization up to Day 14.

Secondary outcomes

  1. Proportion of patients receiving blood transfusion

    The proportion of patients who receive at least one transfusion of red blood cells after randomization up to Day 14. The proportion will be calculated as the number of patients receiving blood transfusion divided by the total number of patients assigned.

    Time frame: From randomization up to Day 14.

  2. Proportion of patients receiving endoscopic hemostasis, transcatheter arterial embolization, surgery for bleeding.

    The proportion of patients who undergo at least one additional hemostatic intervention due to rebleeding after randomization up to Day 14. Additional hemostatic interventions include repeat endoscopic hemostasis, transcatheter arterial embolization, and surgery for rebleeding. The proportion will be calculated as the number of patients receiving at least one additional hemostatic intervention divided by the total number of patients assigned.

    Time frame: From randomization up to Day 14.

  3. All-cause mortality

    The proportion of patients who die from any cause after randomization up to Day 14. The proportion will be calculated as the number of patients who die from any cause divided by the total number of patients assigned.

    Time frame: From randomization up to Day 14.

  4. Incidence of adverse events

    The proportion of patients who experience at least one adverse event after randomization up to Day 14. The proportion will be calculated as the number of patients with at least one adverse event divided by the total number of patients assigned. Adverse events will be coded and classified according to the prespecified adverse-event assessment criteria in the study protocol.

    Time frame: From randomization up to Day 14.

07

Study locations

1 site
08

References and documents

Publications

  • Gralnek IM, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, Laursen SB, Radaelli F, Papanikolaou IS, Curdia Goncalves T, Dinis-Ribeiro M, Awadie H, Braun G, de Groot N, Udd M, Sanchez-Yague A, Neeman Z, van Hooft JE. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021 Mar;53(3):300-332. doi: 10.1055/a-1369-5274. Epub 2021 Feb 10. PubMed 33567467 ↗
  • Mullady DK, Wang AY, Waschke KA. AGA Clinical Practice Update on Endoscopic Therapies for Non-Variceal Upper Gastrointestinal Bleeding: Expert Review. Gastroenterology. 2020 Sep;159(3):1120-1128. doi: 10.1053/j.gastro.2020.05.095. Epub 2020 Jun 20. PubMed 32574620 ↗
  • Barbu LA, Vasile L, Cercelaru L, Surlin V, Mogoanta SS, Mogos GFR, Tenea Cojan TS, Margaritescu ND, Buliman A. Non-Variceal Upper Gastrointestinal Bleeding: A Retrospective Cohort of 364 Cases, Historical Comparison, and Updated Management Algorithm. Life (Basel). 2025 Aug 20;15(8):1320. doi: 10.3390/life15081320. PubMed 40868965 ↗
  • Bai Y, Li ZS. [Standardize the diagnosis and treatment of acute non-variceal upper gastrointestinal bleeding based on the update guidelines]. Zhonghua Nei Ke Za Zhi. 2019 Mar 1;58(3):161-163. doi: 10.3760/cma.j.issn.0578-1426.2019.03.001. Chinese. PubMed 30803170 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 20, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2029
CompletionEst.
Dec 30, 2029
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07776730
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Xingshun Qi (Director of Department of Gastroenterology, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Aug 20, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Aug 20, 2026

Study contacts

Xingshun Qi
Contact
xingshunqi@126.com
18909881019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Keverprazan

Start the discussion